Replies to post #2967 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Ou,

Thanks. I stand corrected, the secondary endpoint is tumor regression. However, this still might mean a very accelerated trial in these 2 unblinded phases.

I guess I need to go back and study how they can judge adverse events for the primary endpoint. Since these are inoperable tumors, I'm stymied. I know death would be one adverse event, but....I guess if I do not find the answer, I will learn it on January 27, 2014 at NWBO's discussion. Again, it is fortunate these are open trials.


Thoughts?